% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Stenzinger:277754,
author = {A. Stenzinger and E. K. Moltzen and E. Winkler and F.
Molnar-Gabor and N. Malek and A. Costescu and B. N. Jensen
and F. Nowak and C. Pinto and O. P. Ottersen and P.
Schirmacher and J. Nordborg and T. Seufferlein and S.
Fröhling$^*$ and A. Edsjö and J. Garcia-Foncillas and N.
Normanno and B. Lundgren and M. Friedman and N. Bolanos and
K. Tatton-Brown and S. Hill and R. Rosenquist},
title = {{I}mplementation of precision medicine in healthcare - a
{E}uropean perspective.},
journal = {Journal of internal medicine},
volume = {294},
number = {4},
issn = {0001-6101},
address = {Oxford [u.a.]},
publisher = {Wiley-Blackwell},
reportid = {DKFZ-2023-01471},
pages = {437-454},
year = {2023},
note = {2023 Oct;294(4):437-454},
abstract = {The technical development of high-throughput sequencing
technologies and the parallel development of targeted
therapies in the last decade have enabled a transition from
traditional medicine to personalized treatment and care. In
this way, by using comprehensive genomic testing, more
effective treatments with fewer side effects are provided to
each patient-i.e., precision, or personalized, medicine. In
several European countries-such as in England, France and
Denmark-the governments have adopted national strategies and
taken 'top-down' decisions to invest in national
infrastructure for precision medicine. In other
countries-such as Sweden and Germany, with regionally
organized healthcare systems-the profession has instead
taken 'bottom-up' initiatives to build competence networks
and infrastructure to enable equal access to precision
medicine. In this review, we summarize key learnings at the
European level on the implementation process to establish
sustainable governance and organization for precision
medicine at the regional, national and EU/international
levels. We also discuss critical ethical and legal aspects
of implementing precision medicine, and the importance of
access to real-world data and performing clinical trials for
evidence generation, as well as the need for improved
reimbursement models, increased cross-disciplinary education
and patient involvement. In summary, precision medicine
represents a paradigm shift, and modernization of healthcare
and all relevant stakeholders-i.e., healthcare, academia,
policy makers, industry, and patients-must be involved in
this system transformation, to create a sustainable,
non-siloed ecosystem for precision healthcare that benefits
our patients and society at large. This article is protected
by copyright. All rights reserved.},
subtyp = {Review Article},
keywords = {Precision medicine (Other) / clinical trials (Other) /
education and training (Other) / ethicolegal aspects (Other)
/ governance (Other) / patient advocacy (Other) /
personalized medicine (Other) / real-world evidence (Other)},
cin = {B340 / HD01},
ddc = {610},
cid = {I:(DE-He78)B340-20160331 / I:(DE-He78)HD01-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37455247},
doi = {10.1111/joim.13698},
url = {https://inrepo02.dkfz.de/record/277754},
}